Login to Your Account



Clinic Roundup


Monday, September 9, 2013

• Cellular Biomedicine Group Inc., of Palo Alto, Calif., reported positive interim results of its Phase I/IIa trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for knee osteoarthritis. The study, which is testing the safety and efficacy of intra-articular injections of autologous haMPCs to reduce inflammation and repair damaged joint cartilage, showed preliminary findings of improvement (P<0.05) from baseline in clinical scores for SF-36, NRS-11 and WOMAC osteoarthritis indices.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription